Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial.

Stuart D. Russell, Paulina Selaru, David A. Pyne, Maha M. Ghazzi, Kenneth D. Massey, Milton Pressler, Alexis Serikoff, Andrew J. S. Coats

Research output: Contribution to journalArticle

53 Citations (Scopus)
Original languageEnglish
Pages (from-to)179-186
Number of pages8
JournalAmerican Heart Journal
Issue number1
Publication statusPublished - 2003

Cite this